Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 expression • CD19 expression
|
Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • FT596